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CLINICAL USEFULNESS OF THE ELECTRONIC MANAGEMENT OF THE
STEM CELL TRANSPLANT SCHEDULE: CLINICAL EVOLUTION OF CAN-
DIDATE PATIENTS
Balsalobre, P.1, Bun˜o, I.1, Serrano, D.1, Carrion, R.1, Carrasco, S.1,
Gomez-Pineda, A.2, Diez-Martin, J.L.1 1. Bone Marrow Transplant
Unit. Hosp. G.U. Gregorio Maran˜o´n, Madrid, Spain; 2. Hematology
Department. Hosp. G.U. Gregorio Maran˜o´n, Madrid, Spain.
From the initial consideration of a candidate to SCT until the SCT
is performed, a long time period (even several months) can elapse.
During this period, several circumstances, either clinical or other
events, can occur, conditioning the viability of the therapeutic proce-
dure. We present here an analysis of the characteristics and evolution
of SCT candidate patients submitted to our SCT unit.Methodology:
In May 2002, we implemented GesTHronica®, a “home-made” soft-
ware for the electronic management of candidate patients presented to
the weekly SCT committee. GesTHronica® allowed us to register
clinical characteristics as well as the clinical evolution of the candidate
patients until their eventual SCT. Results: 173 patients were consec-
utively presented to the SCT committee. The diagnoses were AL/
MDS (24%), lymphoproliferative disorders (43%), MM (19%), solid
tumors (8%), autoimmune diseases (5%) and CML (1%). Addition-
ally, 17 patients transplanted previously were presented as candidates
for a second SCT for the treatment of relapse or secondary malig-
nancy, of which 65% underwent another SCT and 35% underwent
DLI. 115 (60.5%) of the 190 patients presented have already been
treated (63% auto-SCT, 33% allo-SCT, and 4% DLI). The median
time between the program inclusion and SCTwas 4,25months (range
0, 4-13). Twenty-six of 190 patients will receive a SCT (27% of them
already scheduled) and 49/190 (26%) have been excluded from the
SCT program (63% males, median age 50 years [range 4-65]). The
characteristics of this series and the cause of SCT program exclusion
are shown in Table 1.Conclusions: Although the diagnosis as well as
the clinical and administrative management of the candidate patients
for SCT can be conditioned by the local idiosyncrasy of each Insti-
tution, the analysis of the evolution of the patients pre-STC consti-
tutes a useful tool to identify particular events (no mobilization,
disease progression, etc.) which may compromise the chance to re-
ceive a SCT for candidate patients (Table1).
Table 1. Patient Characteristics and Cause of SCT Program Exclusion
Whole
Series
Lympho-
proliferative
Disorders AL/MDS MM
Solid
Tumors
n/% Male 190/59% 81/68% 46/52% 36/47% 16/81%
Median age
in years
(range)
46,5 (4-66) 47 (14-65) 40 (4-65) 57,5 (32-66) 26 (8-30)
Excluded
patients
(%)
49 (26%) 24 (30%) 12 (26%) 8 (22%) 5 (31%)
Median time
to
exclusion
in months:
(range)
3 (0-9,7) 3 (0-9,7) 2,3 (0-8) 5,5 (0,7-9) 1,8 (0-1,9)
Cause of
exclusion
Progression:
n (%)
13 (26%) 7 (29%) 4 (33%) 1 (12,5%) 2 (40%)
Cause of
exclusion
No sufficient
mobilization:
n (%)
11 (22%) 5 (21%) 2 (17%) 3 (37,5%)
Cause of
exclusion
No
Indication
for SCT: n
(%)
12 (24%) 4 (17%) 5 (42%) 1 (12,5%) 2 (40%)
Cause of
exclusion
Co-
morbidity
or death:
n (%)
4 (8%) 2 (8%) 0 (0%) 2 (25%) 0
Cause of
exclusion
Others: n
(%)
8 (16%) 6 (25%) 1 (8%) 1 (12,5%) 0
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CREATING A CUSTOMIZED QUALITY DASHBOARD FOR A BLOOD AND
MARROW TRANSPLANT (BMT) PROGRAM
Nahirny, M., Christian, J. University Medical Center, Tucson, AR.
Many BMT Programs are challenged with identifying a way to
report quality indicators. Providing quantitative data to show how
closely accepted policies and procedures are being followed is an
important tool, but this process can be costly and unreliable if
manual accumulation of data is utilized. Many hospital information
systems lack the specialization to gather transplant-speciﬁc data
and commercial products lack the ﬂexibility to combine data from
multiple sources into one view. Using a combination of a custom-
built transplant information system and hospital laboratory infor-
mation system data, we constructed a web-based dashboard that
displays quarterly measurements of 8 quality indicators:
• inpatient deaths,
• readmits within 30 days of transplant,
• adult transplants with low CD34 collections,
• low concentration CD34 auto harvests,
• infectious disease tests not done within 30 days of collection,
• adverse reactions to infusion,
• ICU visits,
• engraftment.
Data is accumulated automatically without administrative inter-
vention and displayed as comparative quarterly totals, starting from
January 1, 2002. Underlying data can be accessed via hyperlinks so
the circumstances behind non-compliant cases can be investigated.
This center’s experience has shown that these quality indicators
have had a dramatic effect on monitoring BMT operations to
conform with guidelines, since outliers are now much more visible.
It has enabled discovery of operational problems, allowed for their
correction, and provided a measurement of the effectiveness of the
corrective action. It provides a documentation tool for quality
standards as required by the Foundation for the Accreditation for
Cellular Therapy. The visibility of these quality measures is an
important motivating factor in ensuring compliance to procedures.
The dashboard is reviewed quarterly by representatives of all areas
of the BMT program, with discussion and recommendations about
any areas of concern recorded and followed up on. Having a
customized BMT Quality Dashboard may require a time invest-
ment up front, but once such a dashboard is complete, it can be
used with no manual intervention to provide detailed quality indi-
cators and show trends.
506
[Abstract Withdrawn]
507
[Abstract Withdrawn]
508
INFECTIOUS COMPLICATIONS FOLLOWING STEM CELL TRANSPLANT
FOR NON-MALIGNANT DISORDERS USING A NOVEL REDUCED INTEN-
SITY CONDITIONING APPROACH
Witty, S.1, Hayashi, R.1, Barnes, Y.1, Yu L.2, Dalal, J.3, Kamani, N.4,
Pulsipher, M.5, Shenoy, S.1 1. Washington University School of Medi-
cine and St. Louis Children’s Hospital, Saint Louis, MO; 2. Louisiana
State University, New Orleans, LA; 3. Children’s Mercy Hospitals and
Clinics, Kansas City, MO; 4. George Washington University and Chil-
dren’s National Medical Center, Washington, DC; 5. Primary Chil-
dren’s Medical Center, Salt Lake City, UT.
Introduction:Higher rates of graft rejection (GR) and treatment
related toxicities and mortality (TRM) are obstacles to stem cell
transplantation (SCT) for non-malignant disorders. We attempted
to reduce these complications with a novel reduced intensity con-
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